No  ||| S:0 E:3 ||| DT
redistribution  ||| S:3 E:18 ||| NN
of  ||| S:18 E:21 ||| IN
lung  ||| S:21 E:26 ||| NN
blood  ||| S:26 E:32 ||| NN
flow  ||| S:32 E:37 ||| NN
by  ||| S:37 E:40 ||| IN
inhaled  ||| S:40 E:48 ||| FW
nitric  ||| S:48 E:55 ||| FW
oxide  ||| S:55 E:61 ||| FW
in  ||| S:61 E:64 ||| FW
endotoxemic  ||| S:64 E:76 ||| FW
piglets  ||| S:76 E:84 ||| FW
pretreated  ||| S:84 E:95 ||| FW
with  ||| S:95 E:100 ||| IN
an  ||| S:100 E:103 ||| DT
endothelin  ||| S:103 E:114 ||| FW
receptor  ||| S:114 E:123 ||| FW
antagonist  ||| S:123 E:134 ||| FW
Inhaled  ||| S:134 E:142 ||| FW
nitric  ||| S:142 E:149 ||| FW
oxide  ||| S:149 E:155 ||| FW
( ||| S:155 E:156 ||| -LRB-
INO ||| S:156 E:159 ||| NNP
)  ||| S:159 E:161 ||| -RRB-
improves  ||| S:161 E:170 ||| VBZ
ventilation-perfusion  ||| S:170 E:192 ||| JJ
matching  ||| S:192 E:201 ||| NN
and  ||| S:201 E:205 ||| CC
alleviates  ||| S:205 E:216 ||| JJ
pulmonary  ||| S:216 E:226 ||| JJ
hypertension  ||| S:226 E:239 ||| NN
in  ||| S:239 E:242 ||| IN
patients  ||| S:242 E:251 ||| NNS
with  ||| S:251 E:256 ||| IN
acute  ||| S:256 E:262 ||| JJ
respiratory  ||| S:262 E:274 ||| JJ
distress  ||| S:274 E:283 ||| NN
syndrome ||| S:283 E:291 ||| NN
.  ||| S:291 E:293 ||| .
However ||| S:293 E:300 ||| RB
,  ||| S:300 E:302 ||| ,
outcome  ||| S:302 E:310 ||| NN
has  ||| S:310 E:314 ||| VBZ
not  ||| S:314 E:318 ||| RB
yet  ||| S:318 E:322 ||| RB
been  ||| S:322 E:327 ||| VBN
shown  ||| S:327 E:333 ||| VBN
to  ||| S:333 E:336 ||| TO
improve ||| S:336 E:343 ||| VB
,  ||| S:343 E:345 ||| ,
and  ||| S:345 E:349 ||| CC
nonresponse  ||| S:349 E:361 ||| NN
is  ||| S:361 E:364 ||| VBZ
common ||| S:364 E:370 ||| JJ
.  ||| S:370 E:372 ||| .
A  ||| S:372 E:374 ||| DT
better  ||| S:374 E:381 ||| JJR
understanding  ||| S:381 E:395 ||| NN
of  ||| S:395 E:398 ||| IN
the  ||| S:398 E:402 ||| DT
mechanisms  ||| S:402 E:413 ||| NNS
by  ||| S:413 E:416 ||| IN
which  ||| S:416 E:422 ||| WDT
INO  ||| S:422 E:426 ||| NNP
acts  ||| S:426 E:431 ||| NNS
may  ||| S:431 E:435 ||| MD
guide  ||| S:435 E:441 ||| VB
in  ||| S:441 E:444 ||| IN
improving  ||| S:444 E:454 ||| VBG
treatment  ||| S:454 E:464 ||| NN
with  ||| S:464 E:469 ||| IN
INO  ||| S:469 E:473 ||| NNP
in  ||| S:473 E:476 ||| IN
patients  ||| S:476 E:485 ||| NNS
with  ||| S:485 E:490 ||| IN
severe  ||| S:490 E:497 ||| JJ
respiratory  ||| S:497 E:509 ||| JJ
failure ||| S:509 E:516 ||| NN
.  ||| S:516 E:518 ||| .
We  ||| S:518 E:521 ||| PRP
hypothesized  ||| S:521 E:534 ||| VBD
that  ||| S:534 E:539 ||| IN
INO  ||| S:539 E:543 ||| NNP
may  ||| S:543 E:547 ||| MD
act  ||| S:547 E:551 ||| VB
not  ||| S:551 E:555 ||| RB
only  ||| S:555 E:560 ||| RB
by  ||| S:560 E:563 ||| IN
vasodilation  ||| S:563 E:576 ||| NN
in  ||| S:576 E:579 ||| IN
ventilated  ||| S:579 E:590 ||| JJ
lung  ||| S:590 E:595 ||| NN
regions ||| S:595 E:602 ||| NNS
,  ||| S:602 E:604 ||| ,
but  ||| S:604 E:608 ||| CC
also  ||| S:608 E:613 ||| RB
by  ||| S:613 E:616 ||| IN
causing  ||| S:616 E:624 ||| VBG
vasoconstriction  ||| S:624 E:641 ||| NN
via  ||| S:641 E:645 ||| IN
endothelin  ||| S:645 E:656 ||| NNS
( ||| S:656 E:657 ||| -LRB-
ET-1 ||| S:657 E:661 ||| NNP
)  ||| S:661 E:663 ||| -RRB-
in  ||| S:663 E:666 ||| IN
atelectatic ||| S:666 E:677 ||| NN
,  ||| S:677 E:679 ||| ,
nonventilated  ||| S:679 E:693 ||| JJ
lung  ||| S:693 E:698 ||| NN
regions ||| S:698 E:705 ||| NNS
.  ||| S:705 E:707 ||| .
This  ||| S:707 E:712 ||| DT
was  ||| S:712 E:716 ||| VBD
studied  ||| S:716 E:724 ||| VBN
in  ||| S:724 E:727 ||| IN
30  ||| S:727 E:730 ||| CD
anesthetized ||| S:730 E:742 ||| NN
,  ||| S:742 E:744 ||| ,
mechanically  ||| S:744 E:757 ||| RB
ventilated  ||| S:757 E:768 ||| JJ
piglets ||| S:768 E:775 ||| NNS
.  ||| S:775 E:777 ||| .
The  ||| S:777 E:781 ||| DT
fall  ||| S:781 E:786 ||| NN
in  ||| S:786 E:789 ||| IN
oxygenation  ||| S:789 E:801 ||| NN
and  ||| S:801 E:805 ||| CC
rise  ||| S:805 E:810 ||| NN
in  ||| S:810 E:813 ||| IN
pulmonary  ||| S:813 E:823 ||| JJ
artery  ||| S:823 E:830 ||| NN
pressure  ||| S:830 E:839 ||| NN
during  ||| S:839 E:846 ||| IN
a  ||| S:846 E:848 ||| DT
sepsislike  ||| S:848 E:859 ||| JJ
condition  ||| S:859 E:869 ||| NN
( ||| S:869 E:870 ||| -LRB-
infusion  ||| S:870 E:879 ||| NN
of  ||| S:879 E:882 ||| IN
endotoxin ||| S:882 E:891 ||| CD
)  ||| S:891 E:893 ||| -RRB-
were  ||| S:893 E:898 ||| VBD
blunted  ||| S:898 E:906 ||| VBN
by  ||| S:906 E:909 ||| IN
INO  ||| S:909 E:913 ||| NNP
40  ||| S:913 E:916 ||| CD
ppm ||| S:916 E:919 ||| NNS
.  ||| S:919 E:921 ||| .
Endotoxin  ||| S:921 E:931 ||| JJ
infusion  ||| S:931 E:940 ||| NN
increased  ||| S:940 E:950 ||| VBD
serum  ||| S:950 E:956 ||| CD
ET-1 ||| S:956 E:960 ||| CD
,  ||| S:960 E:962 ||| ,
and  ||| S:962 E:966 ||| CC
INO  ||| S:966 E:970 ||| NNP
almost  ||| S:970 E:977 ||| RB
doubled  ||| S:977 E:985 ||| VBD
the  ||| S:985 E:989 ||| DT
ratio  ||| S:989 E:995 ||| NN
between  ||| S:995 E:1003 ||| IN
mRNA  ||| S:1003 E:1008 ||| JJ
expression  ||| S:1008 E:1019 ||| NN
of  ||| S:1019 E:1022 ||| IN
endothelin  ||| S:1022 E:1033 ||| JJ
receptor  ||| S:1033 E:1042 ||| NN
A  ||| S:1042 E:1044 ||| DT
( ||| S:1044 E:1045 ||| -LRB-
mediating  ||| S:1045 E:1055 ||| FW
vasoconstriction ||| S:1055 E:1071 ||| FW
)  ||| S:1071 E:1073 ||| -RRB-
and  ||| S:1073 E:1077 ||| CC
B  ||| S:1077 E:1079 ||| NNP
( ||| S:1079 E:1080 ||| -LRB-
mediating  ||| S:1080 E:1090 ||| JJ
vasodilation  ||| S:1090 E:1103 ||| NN
and  ||| S:1103 E:1107 ||| CC
clearance  ||| S:1107 E:1117 ||| NN
of  ||| S:1117 E:1120 ||| IN
ET-1 ||| S:1120 E:1124 ||| CD
)  ||| S:1124 E:1126 ||| -RRB-
( ||| S:1126 E:1127 ||| -LRB-
ET-A ||| S:1127 E:1131 ||| NNP
/ ||| S:1131 E:1132 ||| NNP
ET-B ||| S:1132 E:1136 ||| NNP
)  ||| S:1136 E:1138 ||| -RRB-
in  ||| S:1138 E:1141 ||| IN
atelectatic  ||| S:1141 E:1153 ||| JJ
lung  ||| S:1153 E:1158 ||| NN
regions ||| S:1158 E:1165 ||| NNS
.  ||| S:1165 E:1167 ||| .
INO  ||| S:1167 E:1171 ||| NNP
caused  ||| S:1171 E:1178 ||| VBD
a  ||| S:1178 E:1180 ||| DT
shift  ||| S:1180 E:1186 ||| NN
in  ||| S:1186 E:1189 ||| IN
blood  ||| S:1189 E:1195 ||| NN
flow  ||| S:1195 E:1200 ||| NN
away  ||| S:1200 E:1205 ||| RB
from  ||| S:1205 E:1210 ||| IN
atelectatic  ||| S:1210 E:1222 ||| JJ
lung  ||| S:1222 E:1227 ||| NN
regions  ||| S:1227 E:1235 ||| NNS
in  ||| S:1235 E:1238 ||| IN
the  ||| S:1238 E:1242 ||| DT
endotoxemic  ||| S:1242 E:1254 ||| JJ
piglets ||| S:1254 E:1261 ||| NNS
,  ||| S:1261 E:1263 ||| ,
but  ||| S:1263 E:1267 ||| CC
not  ||| S:1267 E:1271 ||| RB
during  ||| S:1271 E:1278 ||| IN
ET  ||| S:1278 E:1281 ||| NNP
receptor  ||| S:1281 E:1290 ||| NN
antagonism ||| S:1290 E:1300 ||| NN
.  ||| S:1300 E:1302 ||| .
We  ||| S:1302 E:1305 ||| PRP
conclude  ||| S:1305 E:1314 ||| VBP
that  ||| S:1314 E:1319 ||| IN
INO  ||| S:1319 E:1323 ||| NNP
in  ||| S:1323 E:1326 ||| IN
short-term  ||| S:1326 E:1337 ||| JJ
experiments ||| S:1337 E:1348 ||| NNS
,  ||| S:1348 E:1350 ||| ,
in  ||| S:1350 E:1353 ||| IN
addition  ||| S:1353 E:1362 ||| NN
to  ||| S:1362 E:1365 ||| TO
causing  ||| S:1365 E:1373 ||| VBG
selective  ||| S:1373 E:1383 ||| JJ
pulmonary  ||| S:1383 E:1393 ||| JJ
vasodilation  ||| S:1393 E:1406 ||| NN
in  ||| S:1406 E:1409 ||| IN
ventilated  ||| S:1409 E:1420 ||| JJ
lung  ||| S:1420 E:1425 ||| NN
regions ||| S:1425 E:1432 ||| NNS
,  ||| S:1432 E:1434 ||| ,
increases  ||| S:1434 E:1444 ||| VBZ
the  ||| S:1444 E:1448 ||| DT
ET-A ||| S:1448 E:1452 ||| JJ
/ ||| S:1452 E:1453 ||| CD
ET-B  ||| S:1453 E:1458 ||| JJ
mRNA  ||| S:1458 E:1463 ||| JJ
expression  ||| S:1463 E:1474 ||| NN
ratio  ||| S:1474 E:1480 ||| NN
in  ||| S:1480 E:1483 ||| IN
lung  ||| S:1483 E:1488 ||| NN
tissue ||| S:1488 E:1494 ||| NN
.  ||| S:1494 E:1496 ||| .
This  ||| S:1496 E:1501 ||| DT
might  ||| S:1501 E:1507 ||| MD
augment  ||| S:1507 E:1515 ||| VB
the  ||| S:1515 E:1519 ||| DT
vasoconstriction  ||| S:1519 E:1536 ||| NN
in  ||| S:1536 E:1539 ||| IN
atelectatic  ||| S:1539 E:1551 ||| JJ
lung  ||| S:1551 E:1556 ||| NN
regions ||| S:1556 E:1563 ||| NNS
,  ||| S:1563 E:1565 ||| ,
enhancing  ||| S:1565 E:1575 ||| VBG
the  ||| S:1575 E:1579 ||| DT
redistribution  ||| S:1579 E:1594 ||| NN
of  ||| S:1594 E:1597 ||| IN
pulmonary  ||| S:1597 E:1607 ||| JJ
blood  ||| S:1607 E:1613 ||| NN
flow  ||| S:1613 E:1618 ||| NN
to  ||| S:1618 E:1621 ||| TO
ventilated  ||| S:1621 E:1632 ||| VB
lung  ||| S:1632 E:1637 ||| NN
regions  ||| S:1637 E:1645 ||| NNS
which  ||| S:1645 E:1651 ||| WDT
are  ||| S:1651 E:1655 ||| VBP
reached  ||| S:1655 E:1663 ||| VBN
by  ||| S:1663 E:1666 ||| IN
INO ||| S:1666 E:1669 ||| NNP
.  ||| S:1669 E:1671 ||| .
Such  ||| S:1671 E:1676 ||| JJ
vasoconstriction  ||| S:1676 E:1693 ||| NN
may  ||| S:1693 E:1697 ||| MD
be  ||| S:1697 E:1700 ||| VB
an  ||| S:1700 E:1703 ||| DT
important  ||| S:1703 E:1713 ||| JJ
additional  ||| S:1713 E:1724 ||| JJ
factor  ||| S:1724 E:1731 ||| NN
explaining  ||| S:1731 E:1742 ||| VBG
the  ||| S:1742 E:1746 ||| DT
effect  ||| S:1746 E:1753 ||| NN
of  ||| S:1753 E:1756 ||| IN
INO ||| S:1756 E:1759 ||| NNP
.  ||| S:1759 E:1761 ||| .
